In fact, some additional clinical factors, such as ROI/tumour volume, enhanced morphology, time intensity type of contrast agent, quantitative information from diffusion-weighted MR imaging, might also be good predictors in determining the molecular type (estrogen receptor, progesterone receptor, Ki-67, HER2) of breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.